It was used to treat US President Donald Trump when he contracted this disease.
The Food and Drug Administration (FDA) of the United States has given this Saturday the emergency authorization to Regeneron, the medicine to treat coronavirus popularly known after being used to treat the American president, Donald Trump, when he contracted this disease.
This treatment consists of what is known as a cocktail of antibodies and studies have shown that its early application improves the condition of patients.
The authorization has been issued to treat patients over 12 years old who have the possibility of developing severe symptoms and who are neither hospitalized nor need oxygen, the ‘New York Times’ newspaper has assured.
Another similar drug from the Eli Lilly company was approved earlier this month. Trump promised after leaving the hospital that he would guarantee free access to this drug. The company has received more than 500 million dollars from the US federal government (421.7 million euros approximately) and the first 300,000 doses will be free in the United States, although Americans could pay depending on their insurance to have it applied, as it must be used in a hospital.
According to company calculations, by the end of November they will have enough doses for 80 thousand people and they will be able to treat 200 thousand patients at the beginning of January and 300 thousand at the end of the month, since they have reached an agreement with the Swiss Roche for the production of the medicine.
WE ALSO RECOMMEND YOU READ:
There are 5 strains of SARS-CoV-2 in Mexico
Three of 158 colonies in red by covid-19 with more than 60% positivity
Today marks 8 months since Mexico had its first death from covid
It may interest you:
They catch a teacher beating a young man for not wearing a mask
What does military food taste like? Soldier tastes different foods
Photos and videos of the powerful earthquake that hit Turkey and Greece
Young man sells tamales to a US border agent … in the middle of the wall!
Copyright law strictly prohibits copying all or part of Excelsior’s materials without having previously obtained written permission and without including the link to the original text.
*The article has been translated based on the content of Source link by https://www.excelsior.com.mx/global/eu-aprueba-uso-del-tratamiento-de-regeneron-contra-covid/1418112
. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!